The Antelope (@__OuttaControl_) header
The Antelope (@__OuttaControl_) profile picture

set the gearshift for the high gear of your soul

Joined March 2015
Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)Photo by The Antelope (@__OuttaControl_)
I was bullish on $GLAS at $10. I was wrong, and I'm not going to dress that up. You get it wrong, you own it, you dust yourself off, and you keep working. That's the job. But being wrong on the entry doesn't necessarily mean being wrong on the business. I listened to last night's call in full. Start with governance, because that's where so much of the noise has been. Kazan said the multiple-voting shares expire at the end of June 2027 and he does not intend to ask the board or shareholders to extend them. If that happens, a major source of concentrated voting control disappears. He also went through the related-party arrangements one by one. The Beachfront consulting agreement, which he controls through the Kazan Trust, was terminated September 18. The company acquired the remaining interest in the Lampo property in August 2025, eliminating the NeoStreet related-party lease. The Delavana lease was already terminated, with remaining payment obligations ceasing October 1. The headquarters lease now has a 30-day termination option in the company's favor. Insurance brokerage services are going out to RFP, with a non-related vendor expected by year-end. These aren't just promises to improve governance. Several changes have already happened. Others still need to be completed. I have no interest in personal attacks on the directors. I care about execution and where the business goes from here. The auditor story also made more sense once explained. MGO resigned in September at the company's request so BDO could come in, chosen partly because BDO said it could meet the November 16 deadline. In mid-October, BDO indicated it hadn't finished reviewing the deconsolidation accounting and raised the possibility of filing Q3 without a completed review. Management found that unacceptable and returned to MGO, which had already reviewed the Q2 deconsolidation accounting without requiring material modifications. BDO characterized its unfinished review as an unresolved issue under Canadian disclosure rules. The company disagrees but disclosed BDO's position anyway. BDO never issued an audit or review report during its tenure. The rapid auditor turnover still deserves scrutiny. But the company has now explained the sequence and reported on schedule. Then the operations. Flower yields versus their own historical best quarters: Q2: −25% Q3: −10% Q4 to date: ~−5% Production cost per pound: Q1: $175 Q2: $122 Q3: $109 Meanwhile, quarterly biomass production reached a record 319,000 pounds. The cogeneration unit was offline throughout Q3. No supplemental CO2 and insufficient power to run all the Greenhouse 2 lights. Management expects it back online this week. Roughly 60 days to grow, another 30 to process, and additional time to sell. Those benefits aren't reflected in the reported numbers yet. They also paused hemp. Management acknowledged disappointing economics alongside regulatory uncertainty. I'd rather see them concentrate capital on restoring their core business than keep funding an initiative that isn't delivering, especially with the next phase of federal hemp restrictions expected December 11. Could they have communicated better through all of this? Absolutely. The uncertainty between the October preliminary release and last night's call didn't help investor confidence. But @grahamfarrar stepped up last night, faced the tough questions head-on, and answered them to my satisfaction. Looking in the rearview mirror and pointing fingers has never made me much money. Looking forward, management says it has no plans for further ATM issuance beyond October. If that holds, a source of potential dilution and selling pressure is removed. Management also says its $39.7 million in cash and restricted cash is sufficient to execute the plan, including $20 million of capex, through the seasonally weakest cash period in the first half of 2027. That's the financial runway I'll be watching. Greenhouse 2 is operating. Production costs have fallen sharply. Flower yields are recovering. And Glass House appears on FTSE Russell's official preliminary additions list for the Russell 3000, with reconstitution scheduled to become effective after the December 11 close. It's preliminary, not guaranteed, but another development worth watching. Q4 margins are expected to remain roughly flat, with an improving product mix offset by seasonally weaker flower prices. The real financial test comes in Q1 2027. What would make me wrong? Flower yields stop recovering. Seasonal pricing doesn't improve. The company needs substantially more capital than anticipated. Or the DEA's interpretation of California medical cannabis licensing creates broader obstacles than management expects. Those are real risks. And there's a broader implication for $MSOS and the cannabis sector. Glass House's collapse has contributed to negative sentiment across an already battered industry. If $GLAS can demonstrate that its operational turnaround is real, it could go from being part of the problem to part of the recovery. A rising tide lifts all boats, and this sector could certainly use one. Not advice. Just a guy thinking out loud.
16
5
61
7,113
The most interesting thing from tonight's $GLAS call may be getting overlooked. @grahamfarrar said the DEA show-cause letters have not gone to medical-only operators, but rather operators with both medical and adult-use licenses. Here's why the distinction matters: Glass House's June deconsolidation separated its dual-use retail business from its medical cannabis operations. The company says its remaining operations are medical-only and registered with the DEA. If that distinction holds as the DEA process unfolds, the recent regulatory actions may be less threatening to GLAS's specific structure than the markets have been pricing in. There are still unresolved questions about California's medical patient-certification requirements, and none of this guarantees federal approval or interstate exports. Meanwhile, the operational recovery is getting overlooked. Flower yields versus historical best: Q2: −25% Q3: −10% Q4 to date: ~−5% Production cost/lb: Q1: $175 Q2: $122 Q3: $109 Management expects the offline cogeneration unit to restart this week. Q4 margins are expected to remain roughly flat due to seasonal pricing. The real test of the recovery comes in Q1 2027. The regulatory uncertainty is real. So is the operational progress. Wouldn't surprise me to see $GLAS bungee back up from here, given how much negativity is already priced in. Not advice, just my observations from the call.
2
3
24
2,668
👀👀👀 Democratic U.S. Senate candidate James Talarico said he wants to partner with President Donald Trump on legalizing marijuana if he wins next month's election. "He's for legalizing marijuana, and so am I. I hope we can do that together and expunge the records of people who have been locked up for a crime that doesn't hurt anybody." marijuanamoment.net/talarico…
32
39
10
310
109,220
The Antelope retweeted
The biggest killer on the planet is stress, and I’ve always believed in the medicinal benefits of the cannabis plant. That’s why I support the new CMS Innovation Center initiative expanding clinician-guided access to hemp-derived cannabinoid products. It’s an important step toward learning more about how these plant-based remedies can improve the health and quality of life of older Americans.
217
523
37
3,356
64,506
Weird couple of weeks. I feel better about this industry than I have in a long time and everyone I talk to sounds miserable. I can't square those. Start with the stay, since that's what everyone locked onto. Judge Julius paused the proceeding to decide whether a GAO report belongs in the record. He didn't admit it. He didn't authorize briefing. He said nothing about marijuana's merits. DEA responds by October 13. I get why that reads badly after a year of waiting. But one of the groups that filed that motion is also a petitioner in the D.C. Circuit case against the April order. These people have spent two years hunting for a procedural crack. If this record goes up with a shortcut in it, that's their appeal, and we're still arguing in 2029. Take the two weeks. The other thing I can't shake is how much weight $MSOS is carrying in these conversations. It's a sentiment barometer. It tells you how a small, well-funded group of institutions felt about a headline on a given afternoon. It doesn't tell you whether the tax rules are getting written or whether a state just cleared an obstacle. Those move slowly and don't print a ticker, so nobody discusses them. Here's what happened over the last two or three weeks while everyone watched the chart. Treasury and the IRS put Section 280E guidance on their 2026-27 Priority Guidance Plan. It wasn't on last year's list at all. That's staff assigned to transition year treatment and expense apportionment for mixed operators, which is what determines whether any of this reaches a real business. Alabama's public health committee unanimously withdrew its objection to rescheduling. One fewer state in the road. The CLAIM Act was introduced in the House, joining a Senate version from July. Underinsurance is a real cost-of-capital problem nobody talks about. Raskin and Nunn also filed the CURE Act so past cannabis use stops killing federal security clearances. New York did $512.6 million in Q3. Record quarter, $1.41 billion this year, $4.1 billion program to date, 1,039 licensed retailers. Two years ago people were writing that market's obituary. They also pushed the provisional dispensary deadline out to the end of 2028, which matters if you were staring down a cliff in ninety days. Missouri proposed opening ownership to public companies. Virginia put out draft adult-use rules. Minnesota is running workforce training. And 34 marijuana and hemp measures are sitting in Congress. The stay was a setback and anyone telling you otherwise is selling something. But it got all the oxygen while a federal tax agency assigned staff, a state dropped its objection, a billion-dollar market printed a record, and four more kept grinding on the plumbing. That's a reasonable stretch by any standard I've got. Enjoy the weekend everyone! *as always, not advice, just a guy thinking out loud.
2
5
3
49
2,473
While everyone was focused on the ALJ stay this week, Treasury and the IRS quietly did something more interesting. On September 29, the same day as the stay, they formally made Section 280E guidance an official federal priority for 2026-27. It wasn't on last year's list at all. Now it's one of 121 projects they've committed resources to for the fiscal year. This isn't housekeeping. Treasury has already said it expects a transition rule generally treating the April scheduling change as applying for the entire taxable year in which it took effect. For calendar-year filers that could mean qualifying medical activity gets relief back to January 1, not April 22. They're also writing guidance for companies running both medical and adult-use operations, including how to apportion expenses between activities still subject to 280E and those that aren't. For the MSOs that make up $MSOS, that's one of the biggest practical questions hanging over the sector since April. Worth being clear about the limits. Inclusion sets no deadline. It doesn't eliminate 280E for anyone. And all of it is written against the April order, which is under challenge in the D.C. Circuit. Within 24 hours, one part of the government paused a proceeding over a report about written procedures. Another committed to building the tax plumbing that makes the reform already on the books actually function. Only one of those got any attention. Not advice. Just a guy thinking out loud. themarijuanaherald.com/2026/…
3
10
1
69
3,670
I slept on it and I keep landing in the same place. Marijuana has been federally restricted since 1937 and sat in Schedule I since 1970. Eighty-nine years and fifty-six years. Hold that number in your head for a second before you read the rest. Now look at this year. In April, the Acting Attorney General signed an order moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III. Not proposed. Signed. DOJ simultaneously opened the proceeding on whether the rest of marijuana should follow. Two months later Trulieve became the first US cannabis company to list on the NYSE. Glass House followed three weeks after that. Whatever you think of either company, a major exchange listing changes who is allowed to own the shares, and that is not a small thing after a decade of OTC purgatory. The operating results held up too. Green Thumb did $306.7 million in revenue and $84.3 million of normalized EBITDA. Trulieve did $271 million at a 60% gross margin with $98 million of adjusted EBITDA. Village Farms posted record cannabis revenue, record export sales and record cannabis segment EBITDA. Congress hasn't been idle either. The SAFE Banking Act of 2026 has bipartisan sponsors in both chambers. The CLAIM Act, which protects insurers serving state-legal businesses, was filed in the Senate in July and the House on September 16. And on September 17, Raskin and Nunn introduced the CURE Act to stop past marijuana use from torpedoing a federal security clearance. It picked up a third cosponsor a week later. Then there's the sentence I still find strange to type: The DEA itself walked into that hearing and argued for Schedule III. The government's own position is that marijuana has a currently accepted medical use and cannot stay in Schedule I. Meanwhile CMS started testing CBD access for Medicare beneficiaries in April and revised its supplemental benefits rule so legally permissible cannabis-derived products are no longer categorically excluded. So that's the year. And then yesterday happens. Judge Julius stayed the proceeding while he decides whether to admit a new GAO report into the record. DEA has until October 13 to respond, capped at 20 pages. The motion came from three parties opposed to rescheduling, one of which is a drug testing industry association. Make of that what you will. Here's the part worth actually reading. The GAO report did not find that DEA's scheduling decisions were improper. It reviewed 208 substances from 2020 through 2025. Of the 95 that required an HHS recommendation, 84 had final rules by the end of 2025, and DEA's decision matched HHS in all 84. The remaining 11 were under temporary orders and every one of them was placed in Schedule I in 2026, also matching HHS. What GAO actually found is that DEA and FDA lack written procedures, and it recommended they write some. DOJ, DEA, HHS, FDA and NIH all agreed. That is a report about paperwork. The opponents are arguing that the government's case is only as good as its process. Fine. But the same report shows a perfect alignment record across every completed case it examined. I'm less interested in who is yelling about their $MSOS calls expiring worthless this Friday than in whether the argument survives being read carefully. This one doesn't. Eighty-nine years of prohibition. Medical rescheduling signed. Two major exchange listings. Bipartisan bills moving in both chambers. Medicare touching CBD for the first time. DEA arguing our side of the case. And near the goal line, the judge pauses to consider one more government report. That isn't the thesis breaking, but rather an administrative process behaving like an administrative process. As always not advice, just a guy thinking out loud.
10
6
6
71
5,116
Predictably, Judge Julius' stay is already being turned into something much bigger than the order actually says. And I’d separate that from the usual score-settling and people trying to pile on Anthony V, Anthony M, Todd H, sources, timelines, “pumpers,” etc. Nobody outside the process knows every turn in advance. People are trying to handicap an inherently uncertain regulatory process. Here’s what actually happened: the ALJ paused the proceeding while considering whether to reopen the record to include the new GAO report. DEA has until October 13 to respond. The stay remains in place while that motion is resolved. That’s a procedural development. It is not a ruling against Schedule III and it is not a reversal of the government’s position. In fact, DEA’s final brief **still says marijuana no longer satisfies the requirements for Schedule I and asks the judge to expeditiously recommend Schedule III**. Nothing in today’s order changes that. So yes, this matters if your thesis depends on a very specific near-term date, especially if you’re sitting in short-dated $MSOS options and theta is eating you alive. But jumping from today’s procedural stay to “Schedule III is derailed,” “the midterm strategy is dead,” or “Trump is going to abandon cannabis” is getting way out over your skis. Could this ultimately create a longer delay? Sure. We don’t know yet. But right now, the facts are considerably less dramatic than the reaction I am reading from the Chicken Little X cohort. My read is that Schedule III remains very much on track. Today changed the calendar, not the underlying case.
6
10
2
70
3,476
Could be something, could be nothing, but this statement is certainly gonna be met with a lot of eye rolling. I’ve been buying this dip after hours, but you do you 🤷🏼‍♂️
A senior Trump adviser tells The Marijuana Herald that the president is “not happy” with delays in the marijuana rescheduling process and “will be reaching out to AG Blanche and Terry Cole at the DEA to see what can be done about speeding things up.” themarijuanaherald.com/2026/…
2
1
28
1,425
The Antelope retweeted
Hey @HammanShares invoking Leon Cooperman here is a pretty loaded statement. You brought his name into a discussion about $MSOS selling $GTBIF so what exactly are you implying? Either say it or don’t imply it…
Not our drama. Just ask Leon Cooperman - we are heads down managing and selling. I haven’t heard much about this lately until you brought it up.
3
4
2
34
9,135
The Antelope retweeted
$GTBIF investors to $CURLF/$TRLV investors when the ETF becomes a seller of their security
2
4
1
39
3,432
Looks like $MSOS has finally hit a tipping point with investors. An active fund is a bet on the manager's judgment. That's the entire product. $MSOS @InvestinginCan1 @HammanShares
7
3
43
2,354
Now the $GLAS bull case The thing I keep coming back to is the cost curve. $175 a pound in Q1, $122 in Q2, guided under $100 by year end with $95 as the stated target. That's the only number in this story that matters much to me, because it's the one they actually control and the one nobody else in the industry can replicate. Indoor operators are stuck with their energy bills. Glass House doesn't buy third-party water. Those are facts about the physical asset in Camarillo, not about execution, which means the advantage doesn't erode if management has a bad quarter. Volume is the other half. 246,000 lbs in Q2 against 240k guidance. Management says more than 600k in the back half, with GH2 fully planted and contributing from the end of Q3, exiting the year above a 1.1M lb run rate. So you get roughly a doubling of quarterly output at the same time cost per pound is falling. I don't think the market has sat with what those two curves crossing does to gross profit, partly because it doesn't show up until Q3 and Q4 prints. On the quarter itself, the reported miss was a comparison artifact. Estimates included retail. The reported number only carried retail through the deconsolidation date. ATB ran it like for like and got a revenue beat of 8.3% and adjusted EBITDA up 12.1%. Kazan said outright on the call that prior guidance shouldn't be relied on. The tape traded the headline anyway. The margin issues don't worry me much, although Q3 needs to prove that. There were two of them. Higher trim mix came from genetics they sourced quickly after the raid, and they've gone back to their previous genetics. Separately the CoGen supplying CO2 was offline, which cost more than expected, and it's supposed to return this quarter. Neither reads as a demand or pricing problem to me. We won't wait long to find out if that's right. Now the structural piece, and I want to be careful how I say it because I've only got it from management. On the Q2 call Kazan said they converted every cultivation and processing license to California medical, registered those licenses with the DEA, and now operate under a Schedule III designation. Cup of Coffee Capital quoted the same language independently this morning, so I'm confident that's what was said. Whether it does what he claims it does is a different question, and people are actively arguing about it. But if it's right, there is currently one large-scale, low-cost, DEA-registered cultivator listed on a major US exchange, and it's this one. Worth saying that none of this requires $MSOS to work, or Washington to do anything at all in the next twelve months. Rough math on today's price. Around 88M shares at $8.49 is roughly $750M. Take the exit run rate of 1.1M lbs, $95 cost, today's $211 realized price. That's about $116 a pound of spread, call it $128M of gross profit, against roughly $76M of annualized opex. Somewhere around $50M of EBITDA at current pricing. Fifteen times, on a business whose costs are still coming down, with no interstate, no export and no hemp in the number. Which is where the optionality argument comes in, and I'd hold this more loosely than the rest. Management says they're engaged with potential interstate partners and expect more than one supply agreement by year end. Georgia is $6,500 a pound and California product is available at a tenth of that. Bigs are clearing $400 to $450, so the $211 blended realization is telling you about mix and channel, not about what quality flower fetches. The Cup of Coffee critique is worth taking seriously, and I think it's the smartest bear piece written on this name. He's right that the $14.50 scenario is almost entirely a price assumption wearing a volume costume, and right that contribution profit isn't earnings. Where I part ways is that he treats the price leverage as a flaw. Cost doesn't rise with the sale price. That asymmetry is the reason to own the asset, not a modeling trick. What would make me wrong. Q3 has to show the trim and CoGen problems were actually transitory rather than a permanent step down in what they can realize. Croptober is the bigger risk, and I don't have an answer yet: if California spot falls faster than the cost curve, the spread compresses and the whole thing stalls. And on export, they don't have EU-GMP, which could be at 18 to 36 months and €2.5M to €11M to stand up. So international is a 2028 story regardless of what any deck implies, and anyone underwriting it sooner is underwriting a toll-processing arrangement where most of the margin goes to whoever holds the import license. The honest bear version is that you're paying fifteen times for a bulk cultivator in the hardest cannabis market in the country, with a $100M ATM sitting overhead and no certification for the export market that justifies the multiple.
I’ve been informed that “THE” metric for valuing $GLAS is gross profit because they don't have stores. They really don't have marketing. They really don't have distribution. And so, it's really a gross profit type of business. I’ve also been told that there’s a clear example where $GLAS is making over $20 a share. Seemingly due to MSOs trading at 3-5x gross profit this means that one day $GLAS could be trading for $60-$100 per share. $GLAS is currently $8.50 per share. Of course, TTM gross profit is $56M (roughly $0.60 GP per share). If you applied a 5x multiple on it that would give us a share price of $3.00. $GLAS is currently $8.50 per share. An oddity with that modeling reveals itself when paired with Glass House’s own stated ambition of trying to be the Sunkist of cannabis (or others reference to Dole or Chiquita). Sunkist is a grower owned marketing cooperative. Most of the fruit is still grown by member farms. What Sunkist adds, and what those members pay it to do, is grade and pack to a uniform standard, sell under one brand, allocate supply across buyers and regions, and maintain ongoing accounts with retailers. The co-op exists because selling unnamed fruit at the packing house does not capture what the brand-and-sales layer captures. That layer has costs a farm P&L does not (packing and culls, quality control, a sales organization, brand spend, trade programs with retailers, etc.). The Sunkist example is also a problem because of the legal structure. Sunkist is a grower-owned cooperative. The growers are the owners. New supply generally arrives as new members, and residual value is meant to go back to those members. GH is a public corporation. Residual value is meant to stay with $GLAS shareholders. Those are not the same ownership model or incentive structure. Them being the Sunkist would be extremely dilutive to current shareholders. A better analog is a branded grower-packer such as Dole or Fresh Del Monte. Public companies, owning or contracted production, packing, brand, and sales into retail. That analog has the opposite problem for the GP model. Those companies are not valued on farm gross profit which then brings us back to the inappropriateness of assigning a GH per share value to a multiple assigned to gross profit. As such, those functions and costs are part of the thesis. Farm gross profit is then only the growing layer and the company shouldn’t be solely valued on it.
7
1
9
2,170